

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6415791

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
Name		Execution Date
ALEXION PHARMACEUTICALS, INC.		10/27/2020
RECEIVING PARTY DATA		
Name:	INOZYME PHARMA, INC.	
Street Address:	321 SUMMER STREET, SUITE 400	
City:	BOSTON	
State/Country:	MASSACHUSETTS	
Postal Code:	02210	
PROPERTY NUMBERS Total: 4		
Property Type	Number	
Patent Number:	8846603	
Patent Number:	9540621	
Application Number:	15417590	
Patent Number:	10493135	
CORRESPONDENCE DATA		
Fax Number:	(617)310-9000	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	6174392000	
Email:	docket@nutter.com	
Correspondent Name:	GURUNATHAN LAXMIKANTHAN	
Address Line 1:	155 SEAPORT BLVD	
Address Line 2:	NUTTER MCCLENNEN & FISH LLP	
Address Line 4:	BOSTON, MASSACHUSETTS 02210	
NAME OF SUBMITTER:	GURUNATHAN LAXMIKANTHAN	
SIGNATURE:	/Gurunathan Laxmikanthan/	
DATE SIGNED:	11/23/2020	
Total Attachments: 4		
source=121545_Alexion_Assignment_Executed#page1.tif		
source=121545_Alexion_Assignment_Executed#page2.tif		
source=121545_Alexion_Assignment_Executed#page3.tif		

CONFIRMATORY ASSIGNMENT

THIS CONFIRMATORY ASSIGNMENT is executed to confirm the assignment and transfer of Alexion Pharmaceuticals, Inc. (ASSIGNOR) entire right title and interest in and to certain patent applications and patents to Inozyme Pharma, Inc. (ASSIGNEE) pursuant to the Asset Purchase Agreement dated July 17, 2020, between ASSIGNOR and ASSIGNEE.

WHEREAS, ASSIGNOR is a corporation organized and existing under the laws of the State of Delaware and having its principal place of business at 121 Seaport Blvd, Boston, Massachusetts 02210, USA; and

WHEREAS, ASSIGNEE is a corporation organized and existing under the laws of the State of Delaware and having its principal place of business at 321 Summer Street, Suite 400, Boston, Massachusetts 02210, USA;

WHEREAS, ASSIGNOR holds all right, title and interest in and to certain patents and patent applications as listed on the Exhibit (the PATENTS);

WHEREAS, ASSIGNOR and ASSIGNEE entered into that certain Asset Purchase Agreement dated July 17, 2020, in which ASSIGNOR assigned its entire right, title and interest in and to the PATENTS to ASSIGNEE, and ASSIGNOR and ASSIGNEE each desire to execute this document to confirm that assignment;

NOW, THEREFOR, for good and valuable consideration paid by ASSIGNEE to ASSIGNOR, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR hereby assigns and confirms assignment unto ASSIGNEE, its legal representatives, successors, and assigns, its entire right, title and interest in and to the PATENTS including the right to sue for and recover damages for past infringement thereof, all reissues, re-examinations and extensions thereof, and all rights under any and all international agreements, treaties and laws relating to the protection of industrial property including the right of priority. This assignment is of ASSIGNOR's entire right, title and interest in and to the PATENTS and includes the right to apply for and obtain in all countries any and all Letters Patents, including any extensions or reissues thereof, and the right to procure the grant of all such Letters Patents to ASSIGNEE in its own name, the same to be held and enjoyed by ASSIGNEE for its own use and benefit and the use and benefit of its successors, assigns and legal representatives, to the full end of the term for which said Letters Patent may be granted and/or extended as fully and entirely as the same would have been held by ASSIGNOR had this assignment and sale not been made.

ASSIGNOR hereby grants ASSIGNEE its legal representatives, successors and assigns, the power to insert on this instrument any further identification or information that may be necessary or desirable to comply with the recordation rules of any appropriate and competent authority, including, without limitation, the United States Patent and Trademark Office.

IN WITNESS WHEREOF, ASSIGNOR has caused this Assignment to be executed by its duly authorized officer.

ASSIGNOR

ALEXION PHARMACEUTICALS, INC.

By: Todd Spalding

Name: Todd Spalding

Title: SVP, Head of Intellectual Property

DATE: October 27, 2020

ASSIGNEE hereby confirms and acknowledges receipt of the entire right, title and interest in and to the PATENTS.

ASSIGNEE

INOZYME PHARMA, INC.

By: Henric Bjarko

Name: HENRIC BJARKO

Title: COO

DATE: NOVEMBER 9 - 2020

EXHIBIT

Country	Status	Application No.	Patent No.	Title
European Patent Convention	Granted	11754231.6	2545080	NPP1 FUSION PROTEINS
France	Granted	11754231.6	2545080	NPP1 FUSION PROTEINS
Germany	Granted	11754231.6	2545080	NPP1 FUSION PROTEINS
Great Britain	Granted	11754231.6	2545080	NPP1 FUSION PROTEINS
Hong Kong	Lapsed	14107194.3		NPP1 FUSION PROTEINS
Italy	Granted	502017000079365	2545080	NPP1 FUSION PROTEINS
Patent Cooperation Treaty	Expired	PCT/US2011/028233		NPP1 FUSION PROTEINS
Spain	Granted	11754231.6	2545080	NPP1 FUSION PROTEINS
Turkey	Granted	2017/07910	2545080	NPP1 FUSION PROTEINS
United States	Expired	61/340066		NPP1 FUSION PROTEINS
United States	Expired	61/400954		NPP1 FUSION PROTEINS
United States	Granted	13/583973	8846603	NPP1 FUSION PROTEINS
United States	Granted	14/449364	9540621	NPP1 FUSION PROTEINS
United States	Abandoned	15/361855		NPP1 FUSION PROTEINS
Australia	Lapsed	2011362576	2011362576	NPP1 FUSION PROTEINS
Austria	Lapsed	11861101.1	2683742	NPP1 FUSION PROTEINS
Belgium	Lapsed	11861101.1	2683742	NPP1 FUSION PROTEINS
Brazil	Filed	BR112013023010-0		PRODUCTION OF THIS POLYPEPTIDE BY AN AVIAN CELL
Canada	Lapsed	2829767		NPP1 FUSION PROTEINS
Chile	Granted	2013-02607	54704	FUSION POLYPEPTIDE COMPRISING A TARGETING MOIETY AND A C-TERMINUS CATALYTIC DOMAIN OF NPP1; NUCLEIC ACID ENCODING IT; VECTOR; HOST CELL; PREPARATION METHOD; AND USE THEREOF
China P.R.	Lapsed	201180069050.X	ZL 201180069050.X	NPP1 FUSION PROTEINS
European Patent Convention	Granted	11861101.1	2683742	NPP1 FUSION PROTEINS
France	Granted	11861101.1	2683742	NPP1 FUSION PROTEINS
Germany	Granted	11861101.1	602011055023.3	NPP1 FUSION PROTEINS
Great Britain	Granted	11861101.1	2683742	NPP1 FUSION PROTEINS
Ireland	Lapsed	11861101.1	2683742	NPP1 FUSION PROTEINS
Israel	Lapsed	228295		NPP1 FUSION PROTEINS
Italy	Granted	11861101.1	2683742	NPP1 FUSION PROTEINS
Japan	Granted	2013-557704	5735665	NPP1 FUSION PROTEINS
Japan	Granted	2015-084216	6096826	NPP1 FUSION PROTEINS
Japan	Granted	2017-026961	6484905	NPP1 FUSION PROTEINS
Korea South	Granted	10-2013-7026773	10-1707712	NPP1 FUSION PROTEINS
Korea South	Granted	10-2017-7003612	10-1772366	NPP1 FUSION PROTEINS
Mexico	Granted	MX/a/2013/010392	361434	NPP1 FUSION PROTEINS
Netherlands	Lapsed	11861101.1	2683742	NPP1 FUSION PROTEINS
New Zealand	Lapsed	615070	615070	NPP1 FUSION PROTEINS
Patent Cooperation Treaty	Expired	PCT/US2011/051858		NPP1 FUSION PROTEINS
Russian Federation	Lapsed	2013142583	2601154	NPP1 FUSION PROTEINS
Russian Federation	Filed	2016137265		NPP1 FUSION PROTEINS
Singapore	Lapsed	2013067442	193024	NPP1 FUSION PROTEINS

Country	Status	Application No.	Patent No.	Title
Singapore	Abandoned	10201500208S		NPP1 FUSION PROTEINS
Spain	Granted	11861101.1	2683742	NPP1 FUSION PROTEINS
Sweden	Lapsed	11861101.1	2683742	NPP1 FUSION PROTEINS
Switzerland	Lapsed	11861101.1	2683742	NPP1 FUSION PROTEINS
Turkey	Lapsed	11861101.1	2683742	NPP1 FUSION PROTEINS
United States	Abandoned	14/004294		NPP1 FUSION PROTEINS
United States	Abandoned	14/507124		NPP1 FUSION PROTEINS
United States	Filed	15/417590		NPP1 FUSION PROTEINS
Australia	Lapsed	2015364411		METHODS OF TREATING TISSUE CALCIFICATION
Brazil	Abandoned	BR1120170129280		METHODS OF TREATING TISSUE CALCIFICATION
Canada	Lapsed	2971414		METHODS OF TREATING TISSUE CALCIFICATION
China P.R.	Abandoned	201580069537.6		METHODS OF TREATING TISSUE CALCIFICATION
Colombia	Lapsed	NC2017/0006032		METHODS OF TREATING TISSUE CALCIFICATION
European Patent Convention	Filed	15871159.8		METHODS OF TREATING TISSUE CALCIFICATION
Hong Kong	Abandoned	18105396.9		METHODS OF TREATING TISSUE CALCIFICATION
Japan	Filed	2017-531728		METHODS OF TREATING TISSUE CALCIFICATION
Korea South	Lapsed	10-2017-7019819		METHODS OF TREATING TISSUE CALCIFICATION
Mexico	Abandoned	MX/a/2017/007946		METHODS OF TREATING TISSUE CALCIFICATION
Patent Cooperation Treaty	Expired	PCT/US2015/066646		METHODS OF TREATING TISSUE CALCIFICATION
Russian Federation	Lapsed	2017119466		METHODS OF TREATING TISSUE CALCIFICATION
United States	Expired	62/094943		METHODS OF TREATING TISSUE CALCIFICATION
United States	Expired	62/249781		METHODS OF TREATING TISSUE CALCIFICATION
United States	Granted	15/536880	10493135	METHODS OF TREATING TISSUE CALCIFICATION